Primary Prevention Aspirin Eligibility Under a Contemporary Risk Framework

This cross-sectional study estimates eligibility for low-dose aspirin for primary prevention based on updated Predicting Risk of Cardiovascular Disease Events risk thresholds.

Authors

Institutions

Publication Details

Journal
JAMA Network Open
Published
2026-11-19
DOI
https://doi.org/10.1001/jamanetworkopen.2026.46419
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Primary Prevention Aspirin Eligibility Under a Contemporary Risk Framework

Michael G. Nanna, Sridhar Mangalesh, Abdulla A. Damluji, Sharanya Kaushik et al.
JAMA Network Open
Antiplatelet Therapy and Cardiovascular Diseases
article

Primary Prevention Aspirin Eligibility Under a Contemporary Risk Framework

Michael G. Nanna, Sridhar Mangalesh, Abdulla A. Damluji, Sharanya Kaushik, Raiza Rossi, Shefa Arya Nezhad, Armin Nouri
article en

Abstract

This cross-sectional study estimates eligibility for low-dose aspirin for primary prevention based on updated Predicting Risk of Cardiovascular Disease Events risk thresholds.

JAMA Network OpenVol. 9(11)
Albert Einstein College of Medicine (US), Cleveland Clinic (US), Jacobi Medical Center (US), Yale University (US)
Antiplatelet Therapy and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon